President Donald Trump on Thursday launched TrumpRx, a new direct-to-consumer website intended to serve as a central hub for Americans seeking discounts on prescription medications. The platform is a cornerstone of the administration’s strategy to lower healthcare costs by bypassing traditional insurance middlemen for cash-paying patients.
At a White House unveiling event, the president characterized the initiative as a historic shift in the American medical landscape. “It’s the biggest thing to happen in health care, I think, in many, many decades,” Trump said. He further claimed that millions of citizens would benefit from the platform, stating, “You’re going to save a fortune and this is also so good for overall health care.”
The website, TrumpRx.gov, does not sell pharmaceuticals directly but instead connects consumers to drugmakers offering discounts on their own sites or provides coupons for use at retail pharmacies. At launch, the site features 43 medications from an initial group of five companies: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer. The administration expects to add products from 11 other manufacturers in the coming months.
The discounts are the result of landmark deals where drugmakers agreed to lower prices for Medicaid and offer these direct-to-consumer discounts in exchange for exemptions from certain trade tariffs. These agreements also include provisions to link future U.S. drug prices to the lower rates paid in other developed nations.
Among the most significant price reductions are for popular weight-loss and diabetes treatments. Eli Lilly’s Zepbound injection is listed at $299 per month, down from a retail list price of $1,086. Similarly, Novo Nordisk’s Ozempic and Wegovy injections are priced starting at $199 per month, representing steep cuts from list prices that can exceed $1,300.
However, healthcare analysts suggest the site’s utility may be limited to a specific subset of the population. To access the discounts, users must often certify they are not using government insurance like Medicare and will not seek reimbursement from private insurers. “If they’re able to get a drug covered by their insurance at a relatively affordable copay, then there’s not a great upside to using the TrumpRx website,” said Tricia Cubanski, a researcher at KFF.
The program also faces political and legal hurdles. Senate Democrats have called for an investigation into whether the platform complies with federal law, raising concerns regarding potential illegal kickbacks and conflicts of interest. Critics also pointed out that several drugs on the site are already available as cheaper generics through existing discount services.